FOSAR-NVpEc https://histock.tw/talk/live.aspx?name=gtalk&id=1278 20240529 紫殺

台股 » 個股 » 浩鼎 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

浩鼎

(4174)
可現股當沖
  • 股價
    59.1
  • 漲跌
    ▲0.5
  • 漲幅
    +0.85%
  • 成交量
    288
  • 產業
    上櫃 生技醫療類股
  • 218人加入追蹤

    立即追蹤

  • 本地時間:13:35(已收盤)

     
浩鼎 (4174)籌碼相關-富邦-中和 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

富邦-中和 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2023/12/14181.1000.0081.3012440.41%
2023/12/01183.6000.0083.5012230.45%
2023/11/2100.00182.4082.60-1234-0.43%
2023/11/20181.7000.0082.5012360.42%
2023/11/0200.00182.1082.30-1266-0.38%
2023/10/2400.00180.9081.50-1276-0.36%
2023/10/1900.00279.4079.50-2286-0.70%
2023/10/18180.0000.0078.7012930.34%
2023/10/1300.00181.9081.50-1306-0.33%
2023/10/11180.6000.0080.7013230.31%
2023/10/0600.00181.7081.90-1343-0.29%
2023/10/04180.4000.0080.2013530.28%
2023/10/02082.0000.0082.0003610.00%
2023/09/2500.00182.0081.70-1405-0.25%
2023/09/22081.7000.0080.4004170.00%
2023/09/21180.6000.0080.2014610.22%
2023/09/1400.00182.2082.30-1506-0.20%
2023/09/11180.6000.0080.7015170.19%
2023/08/10185.1000.0084.0015360.19%
2023/08/04184.5000.0084.7015490.18%
2023/07/24189.0000.0089.3015580.18%
2023/07/14191.1000.0090.5016190.16%
2023/07/13194.30094.6090.6016200.16%
2023/07/1200.00195.7094.80-1608-0.16%
2023/07/11197.40197.2096.1006240.00%
2023/07/0700.00195.2096.30-1697-0.14%
2023/07/06296.7000.0095.1027150.28%
2023/07/04198.00198.5096.2007060.00%
2023/07/03195.6000.0096.0016890.15%
2023/06/29297.15497.6396.60-2669-0.30%
2023/06/2800.00391.9394.00-3626-0.48%
2023/06/13289.0000.0089.0026570.30%
2023/06/0500.00291.6090.00-2669-0.30%
2023/06/0200.00187.0086.90-1657-0.15%
2023/05/1900.00283.6083.00-2751-0.27%
2023/05/03486.8500.0086.0048010.50%
2023/04/26085.9000.0084.4008050.00%
2023/04/21089.0000.0085.0007880.00%
2023/04/20289.60187.0087.6017740.13%
2023/04/1900.00392.1390.70-3754-0.40%
2023/04/1400.00390.1788.10-3708-0.42%
2023/04/13291.9000.0090.8026950.29%
2023/04/1200.00287.6091.00-2700-0.29%
2023/04/11484.23284.0084.2026450.31%
2023/04/1000.00180.9080.70-1637-0.16%
AACR 2024年會 浩鼎將發表ADC藥物臨床前數據Anue鉅亨-2024/03/18
浩鼎乳癌針劑新藥三期臨床期中分析 獲可繼續執行建議Anue鉅亨-2024/01/31
浩鼎新任董座梁賡義:借助官學人脈助公司推動生物統計發展Anue鉅亨-2024/01/22
浩鼎 相關文章